As of 2025-11-02, the Relative Valuation of Supernus Pharmaceuticals Inc (SUPN) is 37.30 USD. This relative valuation is based on P/E multiples. With the latest stock price at 55.13 USD, the upside of Supernus Pharmaceuticals Inc based on Relative Valuation is -32.3%.
The range of the Relative Valuation is 30.70 - 44.79 USD.
| Range | Selected | |
| Trailing P/E multiples | 29.9x - 36.9x | 32.6x |
| Forward P/E multiples | 27.6x - 36.4x | 33.4x |
| Fair Price | 30.70 - 44.79 | 37.30 |
| Upside | -44.3% - -18.8% | -32.3% |
| Date | P/E |
| 2025-10-31 | 53.66 |
| 2025-10-30 | 55.00 |
| 2025-10-29 | 54.20 |
| 2025-10-28 | 51.75 |
| 2025-10-27 | 51.32 |
| 2025-10-24 | 51.42 |
| 2025-10-23 | 50.64 |
| 2025-10-22 | 49.32 |
| 2025-10-21 | 49.32 |
| 2025-10-20 | 50.22 |
| 2025-10-17 | 48.83 |
| 2025-10-16 | 48.44 |
| 2025-10-15 | 47.96 |
| 2025-10-14 | 47.91 |
| 2025-10-13 | 47.09 |
| 2025-10-10 | 47.70 |
| 2025-10-09 | 48.19 |
| 2025-10-08 | 46.72 |
| 2025-10-07 | 46.79 |
| 2025-10-06 | 47.02 |
| 2025-10-03 | 47.06 |
| 2025-10-02 | 46.68 |
| 2025-10-01 | 46.76 |
| 2025-09-30 | 46.52 |
| 2025-09-29 | 46.33 |
| 2025-09-26 | 45.78 |
| 2025-09-25 | 45.92 |
| 2025-09-24 | 45.85 |
| 2025-09-23 | 45.58 |
| 2025-09-22 | 45.73 |
| 2025-09-19 | 44.81 |
| 2025-09-18 | 44.90 |
| 2025-09-17 | 43.61 |
| 2025-09-16 | 42.82 |
| 2025-09-15 | 42.82 |
| 2025-09-12 | 44.25 |
| 2025-09-11 | 45.42 |
| 2025-09-10 | 44.98 |
| 2025-09-09 | 44.80 |
| 2025-09-08 | 44.60 |
| 2025-09-05 | 44.78 |
| 2025-09-04 | 44.22 |
| 2025-09-03 | 43.73 |
| 2025-09-02 | 43.35 |
| 2025-08-29 | 43.92 |
| 2025-08-28 | 44.16 |
| 2025-08-27 | 43.87 |
| 2025-08-26 | 43.14 |
| 2025-08-25 | 43.25 |
| 2025-08-22 | 43.69 |